8-K

================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

       Date of Report (Date of earliest event reported) September 8, 2005

                             BSD MEDICAL CORPORATION
             (Exact name of registrant as specified in its charter)

              Delaware                   0-1078375             1590407
          (State or other               (Commission        (IRS Employer
   jurisdiction of incorporation)       File Number)       Identification)

                              2188 West 2200 South
                           Salt Lake City, Utah 84119
          (Address of principal executive offices, including Zip Code)

       Registrant's telephone number, including area code: (801) 972-5555

                                       N/A
          (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

[ ]  Written communications pursuant to Rule 425 under the Securities
     Act (17 CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange
     Act (17 CFR 240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))


[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))

================================================================================



ITEM 7.01     REGULATION FD DISCLOSURE.

BSD Medical Corporation issued a press release on September 8,2005. A copy of
the press release is hereby furnished as Exhibit 99.1 attached hereto.

ITEM 9.01.    FINANCIAL STATEMENTS AND EXHIBITS.

(c)        Exhibits
99.1       Press Release of BSD Medical Corporation dated September 8, 2005



                                   SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Dated:  September 8, 2005

                                                  By: /s/ Hyrum A. Mead
                                                      --------------------------
                                                      President



                                  EXHIBIT INDEX

EXHIBIT NO.    DESCRIPTION
- -----------    -----------------------------------------------------------------
99.1           Press Release of BSD Medical Corporation dated September 8, 2005.

EX-99.1

                                                                    Exhibit 99.1

      BSD MEDICAL EXECUTIVES TO MEET INVESTORS AT NEW YORK'S JAVITS CENTER

    SALT LAKE CITY, Sept. 8 /PRNewswire-FirstCall/ -- BSD Medical Corp. (Amex:
BSM) announced today that the company's President, Hyrum A. Mead, and the
Director of Business Development, Richard A. White, will meet with investors at
the ValueRich Small-cap Financial Expo September 14-15 at the Javits Center in
New York City. BSD's site at the Expo will be location 124. The company will
also make a general presentation Thursday, September 15th, at 11:30 A.M. BSD
Medical was listed on the American Stock Exchange in June, and has recently
become one of the most actively traded stocks on AMEX.

    BSD Medical produces systems that deliver precision-focused RF/microwave
energy to raise temperatures within diseased sites in the body as required by a
variety of medical therapies. BSD pioneered the use of microwave thermal therapy
for the treatment of enlarged-prostate symptoms (BPH), and is responsible for
much of the technology that has created a substantial medical industry based on
that therapy. BSD's primary thrust is in the commercialization of systems used
for the treatment of cancer, and in developments to treat other diseases and
medical conditions. BSD was the recipient of the 2005 Frost and Sullivan
"Technology of the Year Award" for cancer-therapy devices. For further
information visit the BSD website at www.BSDMedical.com.

    Statements contained in this press release that are not historical facts are
forward-looking statements, as that item is defined in the Private Securities
Litigation Reform Act of 1995. All forward-looking statements, including all
projections and expectations of future events, such as expectations for the
successful commercialization of developments for the treatment of cancer and
other diseases and conditions, are subject to risks and uncertainties, some of
which are detailed in part in the Company's filings with the Securities and
Exchange Commission.

SOURCE  BSD Medical Corporation
    -0-                             09/08/2005
    /CONTACT:  Hyrum A. Mead of BSD Medical Corporation, +1-801-972-5555,
fax +1-801-972-5930, investor@bsdmc.com/
    /Web site:  http://www.BSDMedical.com /